Association of lipoprotein-associated phospholipase A2 with coronary calcification among American and Japanese men

Journal of Epidemiology

Volumn 17, Issue 6, 2007, Pages 179-185

  El Saed, Aiman ^a,d   Sekikawa, Akira ^a,b   Zaky, Riad Wahid ^a   Kadowaki, Takashi ^b   Takamiya, Tomoko ^a   Okamura, Tomonori ^b   Edmundowicz, Daniel ^c   Kita, Yoshikuni ^b   Kuller, Lewis H ^a   Ueshima, Hirotsugu ^b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d Health Studies Office   (United States)

Author keywords

1 Alkyl 2 acetylglycerophosphocholine esterase; Asian continental ancestry group; Atherosclerosis; Calcification; Coronary arteriosclerosis; European Continental Ancestry Group

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; LIPOPROTEIN;

ADULT; ARTICLE; ASIAN; BLOOD; CALCINOSIS; CAUCASIAN; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; ETHNOLOGY; HEALTH BEHAVIOR; HUMAN; JAPAN; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREVALENCE; RISK FACTOR; TOMOGRAPHY; UNITED STATES;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CALCINOSIS; CORONARY ARTERY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEALTH BEHAVIOR; HUMANS; JAPAN; LIPOPROTEINS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; TOMOGRAPHY; UNITED STATES;

EID: 37649000915     PISSN: 09175040     EISSN: 13499092     Source Type: Journal    
DOI: 10.2188/jea.17.179     Document Type: Article

References (23)

1. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 1995; 95: 774-82.
2. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A(2) in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005; 25: 923-31.
3. Tjoelker LW, Wilder C, Eberhardt C, Stafforini DM, Dietsch G, Schimpf B, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995; 374: 549-53.
4. Yamada Y, Ichihara S, Fujimura T, Yokota M. Identification of the G994 - > T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism 1998; 47: 177-81.
5. Yamada Y, Yoshida H, Ichihara S, Imaizumi T, Satoh K, Yokota M. Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis 2000; 150: 209-16.
6. Unno N, Nakamura T, Kaneko H, Uchiyama T, Yamamoto N, Sugatani J, et al. Plasma platelet-activating factor acetyl-hydrolase deficiency is associated with atherosclerotic occlusive disease in japan. J Vasc Surg 2000; 32: 263-7.
7. Hiramoto M, Yoshida H, Imaizumi T, Yoshimizu N, Satoh K. A mutation in plasma platelet-activating factor acetylhydrolase (Val279 - >Phe) is a genetic risk factor for stroke. Stroke 1997; 28: 2417-20.
8. Kruse S, Mao XQ, Heinzmann A, Blattmann S, Roberts MH, Braun S, et al. The Ile 198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am J Hum Genet 2000; 66: 1522-30.
9. Koenh. W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany, Circulation 2004; 110: 1903-8.
10. Oei HHS, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MMB, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke - The Rotterdam Study. Circulation 2005; 111: 570-5.
11. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000; 150: 413-9.
12. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005; 26: 137-44.
13. Khuseyenova N, Imhof A, Rothenbacher D, Trischler G, Kuelb S, Scharnagl H, et al. Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis 2005; 182: 181-8.
14. Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, Nauck M, et al. Platelet-activating factor acetyl-hydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors - The Ludwigshafen Risk and Cardiovascular Health Study. Circulation 2005; 111: 980-7.
15. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001; 38: 1302-6.
16. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109: 837-42.
17. O'Donoghue M Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or ator Vastatin Evaluation and Infection Therapy - Thrombolysis In Myocardial Infarction) trial. Circulation 2006; 113: 1745-52.
18. Iribarren C, Gross MD, Darbinian JA, Jacobs DR, Sidney S, Loria CM. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: The CARDIA study. Arteriosclerosis Thrombosis and Vascular Biology 2005; 25: 216-21.
19. Kardys I, Oei HH, Hofman A, Oudkerk M, Witteman JC. Lipoprotein-associated phospholipase A2 and coronary calcification The Rotterdam Coronary Calcification Study. Atherosclerosis 2006;May 3.
20. Sekikawa A, Ueshima H, Zaky WR, Kadowaki T, Edmundowicz D, Okamura T, et al. Much lower prevalence of coronary calcium detected by electron-beam computed tomography among men aged 40-49 in Japan than in the US, despite a less favorable profile of major risk factors. Int J Epidemiol 2005;34:173-9.
21. Worth RM, Kato H, Rhoads GG, Kagan K, Syme SL. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: mortality. Am J Epidemiol 1975; 102:481-90.
22. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Jr., Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827-32.
23. Karasawa K, Harada A, Satoh N, Inoue K, Setaka M. Plasma platelet activating, factor-acetylhydrolase (PAF-AH). Prog Lipid Res 2003; 42: 93-114.